PTK2 and malignant mesothelioma: A recent study showed that in vitro downregulation of Calretinin, a calcium-binding protein expressed in malignant mesothelioma [150] and activator of the FAK signaling pathway [29], increases the susceptibility of malignant mesothelioma cells to the FAK inhibitor Defactinib in vitro [84].